Table 2 Percentage of MGMT promoter hypermethylation, mutation, both, either or neither in the TAM and EC groups

From: MGMT promoter hypermethylation and K-RAS, PTEN and TP53 mutations in tamoxifen-exposed and non-exposed endometrial cancer cases

Groups

Total ( n)

Methyl.

Mutation

Both

Either a

Neither a

TAM

29

31%

(9 of 29)

52%

(15 of 29)

24%

(7 of 29)

62%

(17 of 29)

41%

(12 of 29)

EC

37

38%

(14 of 37)

68%

(25 of 37)

19%

(7 of 37)

86%

(32 of 37)

14%

(5 of 37)

  1. aIndicates that there is a significant (P<0.05) difference between the tamoxifen (TAM) and unexposed to the drug (EC) groups.
Back to article page